Get started
Author

Silvia Colicino

Observed names: Colicino, Silvia, S Colicino, S. Colicino
Observed institutions: Novartis (Switzerland), University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Bristol-Myers Squibb (Switzerland), Imperial College London, University of Milano-Bicocca
ORCID: 0000-0002-0262-6280
Observed ORCID: 0000-0002-0262-6280
OpenAlex ID: A5065353165
Immune Components in Human Milk Are Associated with Early Infant Immunological Health Outcomes: A Prospective Three-Country Analysis
2017 · Daniel Munblit, Marina Treneva, et al. · Nutrients · 80
PDF
Colostrum and Mature Human Milk of Women from London, Moscow, and Verona: Determinants of Immune Composition
2016 · Daniel Munblit, Marina Treneva, et al. · Nutrients · 70
PDF
Effects of short‐term exposure to inhalable particulate matter on DNA methylation of tandem repeats
2014 · Liqiong Guo, Hyang‐Min Byun, et al. · Environmental and Molecular Mutagenesis · 67
Effects of environmental noise exposure on DNA methylation in the brain and metabolic health
2016 · Liqiong Guo, Peng-hui Li, et al. · Environmental Research · 58
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
2025 · Manali Kamdar, Scott R. Solomon, et al. · Journal of Clinical Oncology · 47
PDF
Validation of childhood asthma predictive tools: A systematic review
2019 · Silvia Colicino, Daniel Munblit, et al. · Clinical & Experimental Allergy · 38
Transforming growth factor beta in human milk and allergic outcomes in children: A systematic review
2019 · Ekaterina Khaleva, Zoya Gridneva, et al. · Clinical & Experimental Allergy · 35
Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors
2019 · T. Nakamura, S. Haider, et al. · British Journal of Dermatology · 29
PDF
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
2022 · Ulrich Jaeger, Constantine S. Tam, et al. · Blood Advances · 19
PDF
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.
2024 · Manali Kirtikumar Kamdar, Scott R. Solomon, et al. · Journal of Clinical Oncology · 18
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
2026 · M Lia Palomba, Stephen J Schuster, et al. · The Lancet · 11
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
2025 · Sairah Ahmed, Alejandro Martin Garcia-Sancho, et al. · Blood · 3
PDF
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
2021 · María Diez-Campelo, Luis E. Benlloch, et al. · Blood · 3
55 | Lisocabtagene Maraleucel (liso‐cel) in Patients (pts) With Relapsed or Refractory (r/r) Marginal Zone Lymphoma (mzl) in the Phase 2 Transcend Fl Study
2025 · M. L. Palomba, S. J. Schuster, et al. · Hematological Oncology · 2
PDF
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL
2026 · Sairah Ahmed, Alejandro Martín García-Sancho, et al. · Blood · 1
CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
2025 · M. Lia Palomba, Stephen J. Schuster, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients with Third-Line or Later (3L+) Follicular Lymphoma (FL) from TRANSCEND FL
2026 · Sairah Ahmed, Alejandro Martin García-Sancho, et al. · Transplantation and Cellular Therapy
ORAL ABSTRACT: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
2025 · M. Lia Palomba, Stephen J. Schuster, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
2025 · M. Lia Palomba, Stephen J. Schuster, et al. · Clinical Lymphoma Myeloma & Leukemia
P788: Factors Driving Treatment Decision in Patients With Intermediate-risk Myelodysplastic Syndrome (mds): a Retrospective Analysis From the Grupo Español De Síndromes Mielodisplásicos Spanish Mds Registry
2022 · M. Díez-Campelo, L. Hernandez-Donoso, et al. · HemaSphere
Impact of different definitions of atopic dermatitis
2019 · T. Nakamura, S. Haider, et al. · British Journal of Dermatology
PDF
不同特应性皮炎定义的影响
2019 · T. Nakamura, S. Haider, et al. · British Journal of Dermatology
The application of bayesian and frequentist regularization and variable selection methods for the prediction of asthma in later childhood
2019 · Colicino, Silvia · Spiral (Imperial College London)
PDF
Using a Bayesian approach and external validation to predict persistent asthma at the age of 10 and 20 years in general and high-risk populations
2018 · Silvia Colicino, Cosetta Minelli, et al.
PDF
S59 Predicting asthma in later childhood: a general and high-risk population approach
2017 · S Colicino, C Minelli, et al.
PDF
Works count: 30
Citation count: 481
H-index: 11
I10-index: 11
Year
Topic
Type